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Abstract
Background and aim: Impaired vasodilatation has been suggested to be caused by inhibition of
nitric oxide generation by the recently described asymmetric dimethylarginine (ADMA). In the
present study we wanted to explore whether n-3 polyunsaturated fatty acid (PUFA)
supplementation and/or diet intervention have beneficial influence on endothelial function assessed
as plasma levels of ADMA and L-arginine.
Methods: A male population (n = 563, age 70 ± 6 yrs) with long-standing hyperlipidemia,
characterized as high risk individuals in 1970–72, was included, randomly allocated to receive
placebo n-3 PUFA capsules (corn oil) and no dietary advice (control group), dietary advice
(Mediterranean type), n-3 PUFA capsules, or dietary advice and n-3 PUFA combined and followed
for 3 years. Fasting blood samples were drawn at baseline and the end of the study.
Results: Compliance with both intervention regimens were demonstrated by changes in serum
fatty acids and by recordings from a food frequency questionnaire. No influence of either regimens
on ADMA levels were obtained. However, n-3 PUFA supplementation was accompanied by a
significant increase in L-arginine levels, different from the decrease observed in the placebo group
(p < 0.05). In individuals with low body mass index (<26 kg/m2), the decrease in L-arginine on
placebo was strengthened (p = 0.01), and the L-arginine/ADMA ratio was also significantly reduced
(p = 0.04).
Conclusion: In this rather large randomized intervention study, ADMA levels were not influenced
by n-3 PUFA supplementation or dietary counselling. n-3 PUFA did, however, counteract the age-
related reduction in L-arginine seen on placebo, especially in lean individuals, which might be
discussed as an improvement of endothelial function.
Introduction
Endothelial dysfunction is an early and crucial event in
the pathogenesis of atherosclerosis and cardiovascular
disease [1]. It is reflecting an imbalance between the vaso-
constriction and vasodilatation components and is associ-
ated with several risk factors such as
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The vascular endothelium plays an important role in
maintenance of vasodilatation through the release of
nitric oxide (NO), and central to the development of
endothelial dysfunction is reduced bioactive endothelial
NO. NO is synthesized from L-arginine by NO-synthase,
and the endothelial derived NO is, beyond being an
endogenous vasodilator, important in maintenance of
cardiovascular homeostasis [2-5].
Local administration of L-arginine is known to improve
impaired endothelial function in the coronary [6] and
also in the forearm [7] vascular beds. Furthermore, oral L-
arginine supplementation has been shown to increase the
plasma L-arginine levels with subsequent improvement of
endothelial function in healthy elderly individuals [8].
Raised plasma levels of asymmetric dimethylarginine
(ADMA), an endogenous competitive inhibitor of NO
synthase [9], have been shown to antagonize the endothe-
lium-dependent vasodilatation [9-11], and increased lev-
els of ADMA have been shown to be associated with
increased risk of coronary events in a selected population
[12]. Several studies support the view that the ratio
between L-arginine and ADMA is important for the regu-
lation of endothelial NO-synthase activity [8,13,14].
From epidemiological and clinical studies the importance
of certain dietary patterns with regards to cardiovascular
disease seems obvious [15-17]. Especially, dietary fat and
fatty acids which affect plasma lipids and lipoproteins and
thus are linked to atherosclerosis, are of importance [18].
The clinical benefits of omega-3 polyunsaturated fatty
acids (n-3 PUFA) of marine origin are well recognized
[19,20]. The exact mechanism by which n-3 PUFAs exert
their cardioprotective effect is, however, still not fully
understood. In addition to substantial reduction in serum
triglyceride level, they have been shown to be antithrom-
bogenic and antiarrhythmic, and also to improve
endothelial dysfunction [21-24]. An important role of
dietary factors in modulating endothelial function by
improving endothelium-dependent vasodilatation has
also been suggested by mechanisms still unknown [25-
27].
In the present study we wanted to explore whether n-3
PUFA supplementation and/or diet intervention have
beneficial influence on endothelial function assessed as
plasma ADMA and L-arginine levels in a male population
with long-standing hyperlipidemia. As increased plasma
concentrations of ADMA have been reported to be
strongly related to components of the metabolic syn-
drome [28-31], we wanted to investigate the impact of the
intervention strategies with special emphasis on insulin
resistance and overweight.
Materials and methods
This is a follow-up study of participants from the Oslo
Diet and Anti-smoking study carried out 1972–1977 [32],
comprising 1232 men with hypercholesterolemia (total
cholesterol > 6.45 mmol/L, 80% smokers) and at high risk
for coronary heart disease. The survivors of this popula-
tion were 25 years later invited to participate in the Diet
and Omega-3 Intervention Trial on Atherosclerosis
(DOIT), a 3-year intervention trial aimed to investigate
the effect of n-3 PUFA supplementation and/or dietary
intervention on markers of atherosclerosis [33]. Alto-
gether, a total of 563 subjects, age 64–76 years, were
included in the DOIT study. The study was carried out in
compliance with the Helsinki Declaration and was
approved by the Regional Ethics Committee. All subjects
gave their written informed consent to participate.
Study design
This study had a 2 × 2 factorial design, and the partici-
pants were randomly assigned to receive n-3 PUFA pla-
cebo capsules (corn oil) and no dietary advise (control
group), dietary advice and n-3 PUFA placebo capsules, no
dietary advise and n-3 PUFA capsules, and finally dietary
advice and n-3 PUFA capsules combined. The dietary
advice was individually given by a clinical nutritionist
based on a food frequency questionnaire [34]. Energy
content and nutrient composition of the diet were calcu-
lated from the questionnaires at baseline and the end of
the study (36 months). The dietary advice was given dur-
ing 0–45 minutes at time of randomization, for 30 min-
utes after 3 months, and then further every 6 month.
Individual optimal diet was worked out in cooperation
with the participants and if possible – his wife. The sub-
jects were supported with a margarine rich in polyunsatu-
rated acids (based on sunflower and rapeseed oil) and
vegetable oils (rapeseed oil), free of costs. In addition, to
decrease use of meat, advices to increase intake of vegeta-
bles, fruit and fish, targeting at energy percents from fat
27–30%, protein 15–18% and carbohydrate 50–55% (a
"Mediterranean type" diet), were given. The n-3 PUFA
capsules (Pikasol®, Lube, Denmark) used, contained
about 60% n-3 PUFA, mainly eicosapentaenoic acid
(20:5) and docosahexaenoic acid (22:6) in a ratio 2:1, and
3.4 mg/g tocopherols to avoid peroxidation of the cap-
sules. The placebo capsules (corn oil) contained 56%
linoleic acid (18:2 n-6), 32% oleic acid (18:1 n-9), 10%
palmitic acid (16:0) and 3.0 mg/g tochopherols. Two cap-
sules twice daily, corresponding to a daily intake of either
2.4 g n-3 PUFA or 2.4 g corn oil, were given.
Insulin resistance was estimated according to a Homeos-
tasis model assessment (HOMA) score, calculated with
the following formula: (fasting insulin/7.2)/(22.5/fasting
glucose), as described by Matthews and coworkers [35].Page 2 of 10
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index ≥ 26 kg/m2 (median value of the population).
Blood sampling
Venous blood samples were collected in an overnight fast-
ing state at 7:30 to 10 am. EDTA plasma (0.34 M EDTA-
K3) was prepared for determination of the dimethyl-
arginines and oxidized low density lipoprotein choles-
terol (oxLDL-C), whereas serum was used for nitrate/
nitrite, thiobarbituric-acid-reacting substances, insulin,
glucose and lipid analyses. Plasma and serum were kept
frozen at -70°C for batch analysis, except for the lipid
analyses.
Laboratory methods
Total cholesterol, high density lipoprotein cholesterol,
triglycerides, creatinine, glucose and HbA1c were deter-
mined by conventional methods. Low density lipoprotein
cholesterol was calculated according to Friedewald's for-
mula. Serum fatty acid composition was analyzed in a
sub-set of participants (n = 278) by gas-liquid chromatog-
raphy as previously described [36,37]. Thiobarbituric-
acid-reacting substances were determined by a colorimet-
ric method [12]. Insulin was analyzed using a competitive
radioimmunoassay kit from Linco Research, Inc, St.
Charles, MO, USA. This method is based on a sandwich
ELISA technique. OxLDL-C was measured with an ELISA
kit from Mercodia AB, Uppsala, Sweden. The method is
based on a direct sandwich technique in which two mon-
oclonal antibodies are directed against separate antigenic
determinants on the oxidized apolipoprotein B molecule.
Nitrate/nitrite was analyzed using Total Nitric Oxide
Assay kit (R&D System Europe, Abingdon, UK). Briefly,
this assay is based on the enzymatic conversion of nitrate
to nitrite by nitrate reductase. The reaction is followed by
a colorimetric detection (540 nm) of nitrite as an azo dye
product of the Griess reaction. To minimize interference
with plasma proteins, the samples were ultrafiltrated
through a 12 kDa cut-off filter (VectaSpin Micro 12 K
MWCO, Whatman International Ltd, Maidstone, Eng-
land) prior to the analysis of nitrate/nitrite.
Plasma concentration of L-arginine, ADMA and symmet-
ric dimethylarginine (SDMA) were measured by high per-
formance liquid chromatography and precolumn
derivatization with o-phthaldialdehyde (Sigma Chemicals
Co, St. Louis, MO) as previously described in detail [14].
The recoveries of L-arginine, ADMA and SDMA with this
method were 84%, 91% and 92%, respectively. Detection
limit of the assays were 0,025 μM and the intra- and inte-
rassay coefficients of variation, based on pooled plasma
samples, were ≤ 5% for all.
Statistics
For demographic variables proportions are given. For the
nutrient components, data are presented as mean ± SD
and t-test was used for group comparisons. As several bio-
chemical variables were skewly distributed, these data are
presented as medians and 25,75 percentiles and non-par-
ametric statistics used. Intra-group changes from baseline
to 36 months were evaluated by Wilcoxon test. Between-
group differences were evaluated by Mann-Whitney U test
Table 1: Clinical characteristics, use of medication and fasting lipid variables in the no dietary advice and the dietary advice groups, and 
in the placebo (corn oil) and the n-3 PUFA supplemented groups. Median values (25, 75 percentiles) or proportions are given.
No Diet Intervention Diet Intervention Placebo (corn oil) n-3 PUFA
n 279 279 281 282
Age (yrs)(range) 70 (67, 76) 70 (67, 73) 70 (67, 72) 70 (68, 73)
Verified CVD % 28 28 27 28
Diabetes % 16 14 17 13
Hypertension % 32 29 29 32
Smokers % 33 35 33 35
Medications: %
Statins 25 29 25 29
Acetylsalicylic acid 27 25 28 25
βeta-blockers 19 14 16 17
ACE-inhibitors 17 13 15 15
Nitrates 11 7 7 10
Total Cholesterol (mmol/L) 6.4 (5.8, 7.0) 6.3 (5.5, 6.9) 6.3 (5.6, 6.8) 6.3 (5.7, 7.1)
HDL-C (mmol/L) 1.4 (1.1, 1.6) 1.4 (1.2, 1.6) 1.4 (1.2, 1.6) 1.4 (1.2, 1.6)
LDL-C (mmol/L) 4.1 (3.5, 4.8) 4.0 (3.5, 4.6) 4.1 (3.5, 4.6) 4.1 (3.5, 4.8)
Triglycerides (mmol/L) 1.5 (1.3, 2.1) 1.6 (1.1, 2.0) 1.5 (1.1, 2.0) 1.6 (1.1, 2.1)
CVD: Cardiovascular disease, ACE: Angiotensin converting enzyme, HDL-C: High density lipoprotein cholesterol, LDL-C: Low density lipoprotein 
cholesterolPage 3 of 10
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according to the factorial design, thus diet intervention
was compared to no diet intervention and n-3 PUFA inter-
vention was compared to placebo. The level of statistical
significance was set at p < 0.05. The SPSS 11.0 (SPSS INC.,
Chicago, Illinois, USA) software package was used for sta-
tistical analysis.
Results
Of the 563 included participants, 487 completed the 36
months intervention, 40 had died, 27 dropped out due to
disease states interfering with study follow up and 9 indi-
viduals were unwilling to complete the study period.
Some clinical characteristics and use of medication for the
study population at baseline are presented in Table 1. No
statistically significant differences between the interven-
tion groups were found.
Dietary intake, serum n-3 PUFA and serum lipids
The energy and nutrient composition of the participants'
habitual diet at baseline and after the study period,
obtained from the food frequency questionnaire, are
given in Table 2. At baseline, significantly higher levels of
polyunsaturated fat and the polyunsaturated/saturated fat
ratio were observed in the no dietary advise group com-
pared to the dietary counseling group. At the end of the
study no differences in changes were seen between the
groups for energy and protein intake, whereas the increase
in carbohydrate and the reduction in total fat intake was
significantly greater in the dietary counseling group (p <
0.05 for both). Furthermore, the reduction in saturated
fat, the increase in α-linolenic acid and the increase in the
polyunsaturated/saturated fat ratio in the dietary coun-
seling group, were significantly greater than in the no die-
tary advise group, indicating compliance to the dietary
advice given.
The serum levels of the selected PUFA's at baseline and
after 36 months are presented in Table 3. Significant
increases in eicosapentaenoic acid (20:5n-3), docosahex-
aenoic acid (22:6n-3) and sum n-3 and an improved pol-
yunsaturated/saturated fat ratio were found for subjects
receiving n-3 PUFA supplementation compared to sub-
jects on placebo (p < 0.001 for all), indicating good com-
pliance with the intervention. The reductions obtained in
linoleic acid (18:2n-6), arachidonic acid (20:4n-6) and
sum n-6 were all significantly greater on n-3 PUFA supple-
mentation compared to placebo (p < 0.01 for all). No dif-
ference in changes between the groups in alphalinolenic
acid (18:3n-3) was found.
The triglycerides were significantly more reduced in the
dietary advice group as compared to the no dietary advice
Table 2: Nutrient pattern and some dietary fatty acids (mean ± SD) recorded in the no dietary advice and the dietary advice groups at 
baseline and after 36 months.
No Diet Intervention Diet Intervention
Baseline (n = 279) 36 Months (n = 241) Baseline (n = 279) 36 Months (n = 244) p
Energy (MJ) 8.6 ± 2.0 7.8 ± 1.8c 8.5 ± 2.1 7.7 ± 1.9c ns
Carbohydrates (g/d) 247 ± 65 228 ± 61a 246 ± 71 234 ± 63c ns
% of energy 48.6 ± 6.2 50.0 ± 6.4b 49.1 ± 6.6 51.7 ± 6.8c <0.01
Protein (g/d) 82 ± 19 76 ± 17c 82 ± 19 77 ± 19c ns
% of energy 16.3 ± 2.3 16.8 ± 2.4b 16.6 ± 2.6 17.1 ± 2.5a ns
Fat (g/d) 73 ± 22 62 ± 20c 71 ± 24 58 ± 20c ns
% of energy 31.3 ± 5.5 29.6 ± 5.4c 30.4 ± 5.4 27.6 ± 5.5c <0.05
Fatty acids (g/d)
Saturated fat 27.2 ± 9.9 24.2 ± 8.5c 27.0 ± 10.4 21.4 ± 8.3c <0.01
Monounsaturated fat 27.0 ± 8.1 20.1 ± 6.4c 26.0 ± 8.7 18.4 ± 6.3c ns
Polyunsaturated fat* 13.8 ± 5.0 12.7 ± 4.9c 12.5 ± 5.0 13.1 ± 5.5 <0.001
Omega 6* 10.0 ± 4.1 9.9 ± 4.1 8.9 ± 4.1 9.9 ± 4.7b <0.01
Omega 3† 2.9 ± 1.3 2.5 ± 1.2c 2.8 ± 1.2 2.7 ± 1.1 <0.01
α-linolenic acid* 1.4 ± 0.6 1.4 ± 0.6 1.2 ± 0.6 1.4 ± 0.6c <0.01
P/S ratio* 0.53 ± 0.17 0.55 ± 0.16 0.49 ± 0.16 0.63 ± 0.17c <0.001
MJ: Megajoule, P/S ratio: Polyunsaturated/Saturated fat.
Saturated fatty acids: C14:0, C16:0, C18:0, Omega 6 fatty acids: C18:2, C20:4, Omega 3 fatty acids: C18:3, C20:5, C22:5, C22:6.
* refer to significant intergroup differences at baseline.
a p < 0.05, b p < 0.01, c p < 0.001 refer to within group changes from baseline to 36 months.
p refers to differences in changes from baseline to 36 months between the groups, ns = non significant.
† As subjects were included for trial of n-3 PUFA supplementation, this intake is not expressed in the table.Page 4 of 10
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0.01). After the n-3 PUFA intervention, total cholesterol
and triglycerides were both significantly reduced when
compared to placebo (from 6.3 to 6.2 mmol/L vs 6.3 to
6.3 mmol/L, p < 0.05, and from 1.6 to 1.1 mmol/L vs 1.5
to 1.4 mmol/L, p < 0.01, respectively). Otherwise no
changes were obtained.
Carbohydrates and markers of peroxidation
Glucose, insulin and the HOMA score were significantly
reduced, whereas HbA1c was increased at the end of the
study in all groups, but no differences in changes between
any intervention groups were found. No effects of either
intervention strategies were furthermore observed for
thiobarbituric-acid-reacting substances, oxLDL-C and
nitrate/nitrite (Table 4).
Dimethylarginines
There were no group differences in the levels of ADMA, L-
arginine, the L-arginine/ADMA ratio or SDMA at baseline
(Table 4). There were also no differences in these variables
in subjects treated with statins, angiotensin converting
enzyme inhibitors, β-blockers or nitrates, when compared
with untreated individuals at baseline.
At the end of the study, no changes in the dimethyl-
arginines or L-arginine were observed in the dietary advice
group as compared to the no dietary advice group.
In the n-3 PUFA supplementation group no changes in
the levels of dimethylarginines were found. However, a
significant reduction in L-arginine levels was observed in
the placebo group (p < 0.01), significantly different from
the increase in the n-3 PUFA group (p < 0.05). Analyzed
by single group comparisons, borderline significant
increased levels of L-arginine were found in the n-3 PUFA
treatment group alone as compared to control (p =
0.065).
Analyzed separately according to being overweight or not,
in subjects with low body mass index (< 26 kg/m2) the
reduction in L-arginine levels on placebo compared to n-
3 PUFA supplementation, was more pronounced (p =
0.01) and the L-arginine/ADMA ratio was significantly
more reduced (p = 0.040) (Figure 1). No differences
between the intervention groups were recorded in these
variables at baseline in this respect.
Analyzed according to quartiles of the HOMA score no
effects of the interventions strategies were recorded at any
level of insulin resistance.
Discussion
The present study was undertaken to explore whether
long-term n-3 PUFA supplementation and/or dietary
intervention had beneficial influence on plasma levels of
ADMA and L-arginine/ADMA ratio, thus an improvement
of endothelial function.
In response to n-3 PUFA supplementation, an increase in
plasma L-arginine levels was observed, in contrast to the
decrease seen in the placebo group, most pronounced in
individuals not overweighed. No effects of dietary changes
towards a Mediterranean type diet on these variables were
found in this population of elderly high risk men. Satis-
factory compliance with both regimens was demonstrated
by changes in nutrient pattern and in the changes in the
serum fatty acid profile.
To our knowledge this is the first report on which effects
of n-3 PUFA supplementation and/or dietary counseling
on the levels of L-arginine and dimethylarginines have
been evaluated. It has previously been focused on a poten-
Table 3: Levels of some selected serum fatty acids (g/L) at baseline and after 36 months, in the placebo (corn oil) and the n-3 PUFA 
supplemented groups. Median values (25, 75 percentiles) are given.
placebo (corn oil) n-3 PUFA
Baseline (n = 139) 36 Months (n = 114) Baseline (n = 139) 36 Months (n = 122) p
Linoleic acid, 18:2n-6 1.59 (1.33, 1.82) 1.58 (1.36, 1.81) 1.70 (1.47, 1.96) 1.47 (1.24, 1.70)b <0,001
AA, 20:4n-6 0.23 (0.20, 0.27) 0.25 (0.21, 0.30)b 0.22 (0.19, 0.27) 0.21 (0.18, 0.25)b <0,001
ALA, 18:3n-3 0.030 (0.022, 0. 39) 0.031 (0.024, 0.037) 0.033 (0.026, 0.043) 0.031 (0.025, 0.042) ns
EPA, 20:5n-3 0.076 (0.049, 0.13) 0.070 (0.041, 0.11)a 0.081 (0.051, 0.14) 0.22 (0.17, 0.27)b <0,001
DHA, 22:6n-3 0.14 (0.12, 0.19) 0.14 (0.11, 0.18) 0.17 (0.12, 0.20) 0.20 (0.16, 0.23)b <0,001
Sum n-6 1.82 (1.57, 2.11) 1.86 (1.58, 2.06) 1.94 (1.68, 2.22) 1.68 (1.44, 1.94)b <0,001
Sum n-3 0.27 (0.20, 0.38) 0.26 (0.21, 0.35) 0.31 (0.22, 0.41) 0.49 (0.39, 0.57)b <0,001
Ratio omega-6/omega-3 6.85 (4.75, 9.27) 7.08 (5.35, 9.44) 6.36 (4.70, 8.37) 3.40 (2.69, 4.28)b <0,001
Total fatty acids in serum 5.31 (4.58, 6.22) 5.04 (4.40, 5.70) 5.29 (4.60, 6.25) 4.73 (4.05, 5.59)b 0.011
AA: Arachidonic acid, ALA: Alphalinolenic acid, EPA: Eicosapentaenoic acid, DHA: Docosahexaenoic acid.
a p < 0.05, b p < 0.01 refer to within group changes from baseline to 36 months
p: refers to differences in changes from baseline to 36 months between the groupPage 5 of 10
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Table 4: Dimethylarginines and some associated variables, markers of peroxidation and carbohydrates at baseline and after 36 months according to the intervention strategies. 
Median values (25, 75 percentiles) are given.
No Diet Intervention Diet Intervention Placebo (corn oil) n-3 PUFA
Baseline 
(n = 279)
36 Months 
(n = 241)
Baseline 
(n = 279)
36 Months 
(n = 244)
Baseline 
(n = 281)
36 Months 
(n = 239)
Baseline 
(n = 282)
36 Months 
(n = 248)
p1 p2
ADMA (μM) 1.42 (1.11, 1.75) 1.41 (1.14, 1.78) 1.38 (1.15, 1.76) 1.40 (1.12, 1.77) 1.38 (1.10, 1.77) 1.39 (1.14, 1.80) 1.39 (1.16, 1.75) 1.42 (1.13, 1.76) 0.62 0.93
SDMA (μM) 0.23 (0.17, 0.33) 0.26 (0.17, 0.38)* 0.23 (0.16, 0.34) 0.26 (0.17, 0.39) 0.22 (0.16, 0.33) 0.26 (0.18, 0.38) 0.23 (0.17, 0.34) 0.26 (0.17, 0.39) 0.24 0.71
L-arginine (μM) 85 (76, 97) 85 (76, 94) 86 (76, 98) 86 (75, 99) 87 (76, 97) 84 (75, 95) † 85 (77, 97) 88 (76, 97) 0.80 <0.05
L-arg/ADMA 62 (48, 76) 59 (47, 77) 61 (49, 78) 61 (49, 80) 62 (49, 78) 60 (47, 77) 62 (48, 77) 61 (49, 80) 0.97 0.32
Nitrate/nitrite (μM) 26.2 (22.0, 34.4) 27.6 (21.7, 34.3) 25.9 (21.5, 35.2) 26.4 (21.7, 34.4) 25.5 (21.6, 36.1) 27.3 (21.5, 34.8) 27.4 (21.9, 34.3) 27.1 (21.9, 34.2) 0.99 0.65
oxLDL-C (U/L) 68 (57, 80) 61 (47, 74) ‡ 65 (53, 84) 59 (48, 75) ‡ 65 (54, 82) 60 (47, 74) ‡ 69 (55, 82) 60 (49, 74) ‡ 0.49 0.25
TBARS (μmol/L) 1.20 (0.96, 1.68) 1.28 (0.96, 1.76) 1.20 (0.96, 1.60) 1.20 (0.88, 1.60) 1.20 (0.96, 1.60) 1.28 (0.96, 1.68) 1.20 (0.96, 1.68) 1.20 (0.88, 1.68) 0.75 0.73
Glucose (mmol/L) 5.6 (5.3, 6.3) 5.5 (5.0, 6.1) † 5.6 (5.3, 6.2) 5.4 (5.0, 5.9) ‡ 5.6 (5.3, 6.3) 5.5 (5.0, 6.1) ‡ 5.6 (5.2, 6.1) 5.5 (5.0, 6.0) ‡ 0.08 0.75
HbA1c (%) 5.6 (5.3, 5.9) 5.7 (5.5, 6.1) ‡ 5.6 (5.3, 5.8) 5.7 (5.5, 5.9) ‡ 5.6 (5.4, 5.9) 5.7 (5.5, 6.1) ‡ 5.5 (5.3, 5.8) 5.7 (5.5, 5.9) ‡ 0.41 0.31
Insulin (pmol/L) 112 (92, 153) 109 (85, 139) ‡ 121 (94, 154) 105 (83, 131) ‡ 120 (94, 155) 109 (87, 143) ‡ 113 (92, 152) 103 (79, 131) ‡ 0.28 0.35
HOMA score 4.0 (3.0, 5.7) 3.7 (2.8, 5.0) ‡ 4.3 (3.2, 5.5) 3.6 (2.7, 4.7) ‡ 4.3 (3.3, 5.8) 3.7 (2.9, 5.3) ‡ 4.0 (3.0, 5.6) 3.5 (2.7, 4.6) ‡ 0.16 0.40
Creatinine (μmol/L) 88 (80, 96) 96 (89, 109) ‡ 88 (81, 99) 97 (89, 109) ‡ 88 (80, 96) 96 (87, 106) ‡ 88 (81, 98) 97 (89, 110) ‡ <0.05 0.21
BMI (kg/m2) 26.5 (24.3, 28.7) 26.6 (24.6, 29.3) 26.5 (24.0, 28.5) 26.2 (23.8, 28.7) 26.6 (23.9, 28.8) 26.8 (24.3, 29.3) 26.4 (24.2, 28.4) 26.3 (24.3, 28.4) <0.05 0.071
SBP (mmHg) 149 (134, 160) 143 (132, 156) ‡ 147 (137, 161) 142 (128, 154) ‡ 148 (134, 161) 142 (129, 156) ‡ 148 (138, 160) 142 (131, 154) ‡ 0.40 0.48
DBP (mmHg) 83 (76, 91) 79 (72, 87) ‡ 84 (77, 91) 78 (70, 86) ‡ 84 (77, 91) 78 (70, 87) ‡ 84 (77, 91) 78 (71, 86) ‡ 0.09 0.40
TBARS: thiobarbituric-acid-reacting substances, BMI: Body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure.
* p <0.05, † p <0.01, ‡ p <0.001, refers to intra group changes from baseline to 36 months.
p1 and p2, refers to differences in changes from baseline to 36 months between diet and no-diet intervention, and PUFA and placebo supplementation, respectively.
Nutrition & Metabolism 2006, 3:4 http://www.nutritionandmetabolism.com/content/3/1/4tial role of n-3 PUFA in modulating vascular contraction
and vasodilatation [38-40]. Increased endogenous NO
production following supplementation with fish oil has
been reported [41], which may be responsible for the
improvement in endothelial function observed with n-3
PUFA [21,23]. Our hypothesis was that this might be
through an effect on ADMA levels, accompanied by an
increased production of NO. However, the improvement
may rather be through increased L-arginine levels as dem-
onstrated in the present study. Previous studies have
shown that administration of L-arginine has improved
impaired endothelial function and inhibited the progres-
sion of atherosclerosis in humans, especially in healthy
elderly individuals, as well as in experimental animal
studies [2,6,8,13]. In line with our observations with n-3
PUFA, Bode-Boger et al. demonstrated that dietary L-
arginine supplementation elevated the L-arginine/ADMA
ratio by increasing plasma L-arginine levels, while the
L-arginine and L-arginine/ADMA ratio at baseline and after 36 months in subjects with A) low body mass index (<26 kg/m2) and B) high body mass index (>26 kg/m2) on placebo (corn oil) (n = 101) or n-3 PUFA supplementation (n = 110)Figure 1
L-arginine and L-arginine/ADMA ratio at baseline and after 36 months in subjects with A) high body mass index (>26 kg/m2) 
and B) low body mass index (<26 kg/m2) on placebo (corn oil) (n = 101) or n-3 PUFA supplementation (n = 110). Median val-
ues are given. p-values refer to differences in changes from baseline to 36 months between the groups.
A
B
L-Arginine (μM)
70
78
86
94
102
Placebo n-3 PUFA
L-Arg/ADMA ratio
30
50
70
90
Placebo n-3 PUFA
Baseline
36 Months
P=0.52 P=0.52
L-Arginine (μM)
70
78
86
94
102
Placebo n-3 PUFA
L-Arg/ADMA ratio
30
50
70
90
Placebo n-3 PUFA
Baseline
36 Months
P=0.010 P=0.040Page 7 of 10
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anisms not known. Previous studies using different inter-
vention principles known to improve endothelial
dysfunction, have revealed that to influence ADMA levels
directly are difficult [2,14,42]. Why the beneficial effect of
n-3 PUFA on L-arginine and subsequently on the L-
arginine/ADMA ratio was strengthened in normal (non-
overweight) individuals is not easily explainable. We have
previously demonstrated that overweight and insulin
resistant individuals have elevated levels of ADMA and
reduced L-arginine/ADMA ratio [31], and our hypothesis
was that these subjects would benefit more from the inter-
vention strategies.
Several studies have reported correlation between ADMA
and serum lipid variables [13,14,43,44]. Despite the
reduction in intake of dietary fat and triglycerides after
long term dietary intervention and in triglycerides and
total cholesterol after n-3 PUFA supplementation, this
was not accompanied by reduction in ADMA levels or
increased nitrate/nitrite concentrations in our study.
The so called Mediterranean diet has previously been
reported to be favorable regarding recurrence of myocar-
dial infarction in the LYON Heart Study [16,45], and for
delaying all cause of death after a heart attack in the GISSI
study [46]. The exact mechanism for the reduced risk for
cardiovascular disease after dietary changes towards the
Mediterranean diet is not known. Fard et al. have recently
demonstrated acute elevation of ADMA levels and
impaired endothelial function in response to high-fat
meal in patients with type 2 diabetes [11]. They proposed
that the increase in ADMA levels resulted from a reduction
in the expression or enzyme activity of dimethylarginine
dimethylaminohydrolase (DDAH), an enzyme selectively
responsible for degradation of ADMA [47]. Down regula-
tion of DDAH has also been associated with oxidative
stress [29,48], which, however was not affected in our
study when measured as peroxidation markers. In accord-
ance with our results, Amgring et al. did not find any ben-
eficial effects either on oxidative stress evaluation or in
plasma concentrations of insulin and glucose in their
short-term diet intervention study of healthy subjects
[49]. The lack of effect of diet in our study might also be
due to the fact that there was a tendency towards
improved diet also in the group receiving no dietary
advice.
Recently, elevated ADMA concentrations have been
linked to metabolic variables related to cardiovascular risk
factors like glucose, insulin and insulin resistance
[14,30,31,50], and glucose per se has been shown impor-
tant in the regulation of DDAH and ADMA [29]. Lack of
effects of both intervention principles on these variables
may, therefore, explain why ADMA levels were not
affected in the present study.
The modest effects found in our study may be explained
by the heterogeneity of this older population, survivors
from a population at high risk for cardiovascular disease,
using a broad spectrum of medication that may affect the
levels of ADMA and L-arginine through mechanisms not
known, although no influence of the recorded medica-
tions could be seen. However, the present study confirms
that the study subjects at baseline had ADMA levels simi-
lar to what have been shown in subjects with hypercholes-
terolemia, with almost 2-fold higher levels than in young
healthy subjects [14]. This may have pathophysiological
significance, as they are within the range shown to inhibit
the activity of NO-synthase [51-53].
In conclusion, the increased levels of L-arginine observed
after long-term n-3 PUFA supplementation, counteracting
the age related decrease seen in the placebo group, espe-
cially in lean individuals, might be discussed as an
improvement of endothelial function. Neither long-term
n-3 PUFA supplementation nor dietary counseling
towards a Mediterranean type diet had effect on the levels
of ADMA in our population of elderly high risk men.
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